Released May 9, 2022, before the open
10-Q filed May 9, 2022, 39 days after period end · 0001628280-22-013333
Q1 2022 · 10-Q
Revenue$3.92M$3.92M +1,270.6% vs Q1 2021+449.8% vs Q4 2021
Net Income-$26.91M-$26.91M N/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.65-$0.65 N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$27,804,000N/M
Operating Cash Flow$271,534,000N/M
Free Cash Flowderived$271,287,000N/M
Margins · derived
Operating margin-709.3%+7378.1 pt vs Q1 2021
Net margin-686.6%+7350.5 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|
| Revenue | $3.92M | $286.00K | $0.00 |
| Net Income | -$26.91M | -$22.99M | -$13.95M |
| EPS Diluted | -$0.65 | -$0.62 | -$2.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR